Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.55 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12047565 | 0.92 | DPP4 (0.59) | DPP4KCNH2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL8214898 | 0.87 | DPP4 (0.73) | DPP4CYP1A2CYP3A4CYP2D6OPRM1 | |
| SCHEMBL8206959 | 0.86 | DPP4 (0.54) | DPP4KCNH2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL8215883 | 0.84 | DPP4 (0.70) | DPP4KCNH2 | |
| SCHEMBL2609251 | 0.84 | DPP4 (0.68) | DPP4KCNH2 | |
| SCHEMBL12290555 | 0.84 | DPP4 (0.68) | DPP4KCNH2 | |
| SCHEMBL8214983 | 0.84 | DPP4 (0.82) | DPP4KCNH2 | |
| SCHEMBL8217596 | 0.83 | DPP4 (0.71) | DPP4KCNH2 | |
| SCHEMBL8214899 | 0.82 | DPP4 (0.51) | DPP4KCNH2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL8213760 | 0.82 | DPP4 (0.68) | DPP4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071583-B2 | Pyrrolo[3,2-D] pyrimidines as DPP-IV inhibitors for the treatment of diabetes mellitus | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-06 | — | — | US | disclosed |
| US-20090325926-A1 | PYRROLO[3,2-D] PYRIMIDINES AS DPP-IV INHIBITORS FOR THE TREATMENT OF DIABETES MELLITUS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-12-31 | — | — | US | disclosed |
| WO-2008017670-A1 | PYRROLO [3, 2 -D] PYRIMIDINES AS DPP-IV INHIBITORS FOR THE TREATMENT OF DIABETES MELLITUS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325926-A1 | PYRROLO[3,2-D] PYRIMIDINES AS DPP-IV INHIBITORS FOR THE TREATMENT OF DIABETES MELLITUS | DPP4, DPP3, DPP7 | DPP4 1/4885KCNH2 3076/4885CYP1A2 1325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.